Oncobiologics (NASDAQ:OTLK) Releases Earnings Results

Key Points

• Oncobiologics missed quarterly estimates, reporting an adjusted loss of $0.09 per share versus the expected $0.08 loss, while revenue of $0.01 million fell well short of the $0.97 million consensus.
• FDA approval for LYTENAVA gives the company an entry point into the U.S. wet age-related macular degeneration market. Management projects $50 million–$75 million in first-year U.S. sales and more than $500 million in peak annual sales by 2030.
• Commercialization carries significant financial risks: the company had $11.2 million in cash at June 30, expects substantially higher selling expenses, and faces reimbursement and pricing challenges in Europe. Analysts maintain a consensus “Hold” rating with an average price target of $4.65.

Oncobiologics (NASDAQ:OTLK - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01), FiscalAI reports. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.97 million.

Here are the key takeaways from Oncobiologics' conference call:

• FDA approval secured for LYTENAVA, the only FDA-approved ophthalmic bevacizumab formulation for wet AMD in the U.S., positioning Outlook Therapeutics to target the established market for repackaged off-label bevacizumab.
• Management is targeting more than $500 million in peak U.S. annual sales by 2030, with potential upside of nearly $300 million if compounded bevacizumab availability is disrupted. The company expects a first-year U.S. revenue ramp of $50 million-$75 million, accelerating after an anticipated permanent J-code in April 2027.
• The company plans a measured U.S. launch later this year, including approximately 30 customer-facing commercial hires and 20 field reimbursement personnel. It expects LYTENAVA’s wholesale acquisition price to be below $500 per vial and is preparing payer engagement, supply, and coding infrastructure.
• Outlook reported only $11.2 million in cash at June 30, although a subsequent $55 million offering is expected to provide approximately $51.1 million in net proceeds. Quarterly SG&A is expected to roughly double by the end of 2026 and rise another 10% in 2027 to support commercialization.
• European commercialization remains challenging because of reimbursement constraints, pricing pressure, and local compounding practices. Management expects Europe to represent less than one-quarter of the U.S. opportunity by 2030, despite improving unit sales and planned expansion into additional markets.

Oncobiologics Price Performance

Oncobiologics stock traded down $0.13 during midday trading on Friday, reaching $0.76. The company had a trading volume of 104,469,209 shares, compared to its average volume of 13,115,878. Oncobiologics has a 12-month low of $0.16 and a 12-month high of $3.39. The company has a market capitalization of $112.39 million, a P/E ratio of -0.65 and a beta of 0.82. The firm's fifty day simple moving average is $1.31 and its 200-day simple moving average is $0.70.

Insider Activity at Oncobiologics

In other news, Director Faisal Ghiath Sukhtian bought 95,398 shares of Oncobiologics stock in a transaction on Wednesday, July 29th. The stock was acquired at an average price of $1.05 per share, with a total value of $100,167.90. Following the completion of the acquisition, the director directly owned 220,972 shares of the company's stock, valued at $232,020.60. The trade was a 75.97% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ghiath M. Sukhtian bought 8,539,709 shares of the firm's stock in a transaction dated Thursday, May 28th. The stock was purchased at an average price of $0.59 per share, for a total transaction of $5,038,428.31. Following the transaction, the director owned 22,092,068 shares of the company's stock, valued at approximately $13,034,320.12. This represents a 63.01% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have acquired 8,664,107 shares of company stock valued at $5,162,666. 1.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Oncobiologics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. raised its position in shares of Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company's stock valued at $126,000 after buying an additional 44,063 shares during the last quarter. AQR Capital Management LLC grew its stake in Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company's stock valued at $103,000 after acquiring an additional 25,351 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company's stock valued at $39,000 after acquiring an additional 21,941 shares in the last quarter. Institutional investors and hedge funds own 11.20% of the company's stock.

Analyst Upgrades and Downgrades

OTLK has been the subject of a number of analyst reports. Ascendiant Capital Markets upped their price target on Oncobiologics from $6.00 to $10.00 and gave the stock a "buy" rating in a report on Thursday, June 11th. Wall Street Zen raised Oncobiologics from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Weiss Ratings upgraded Oncobiologics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday. HC Wainwright increased their target price on Oncobiologics to $1.60 and gave the company a "neutral" rating in a research report on Monday, July 27th. Finally, BTIG Research reissued a "buy" rating and issued a $4.00 price target on shares of Oncobiologics in a research note on Friday. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $4.65.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics' research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source